New drug combo challenges standard treatment for hepatitis d
NCT ID NCT07142811
Summary
This study is testing whether a new two-drug combination (Tobevibart+Elebsiran) works better than the current standard treatment (bulevirtide) for people with chronic hepatitis D virus (HDV) infection. About 100 adults with stable liver disease will receive either the new combination or the standard treatment for 48 weeks. Researchers will measure whether the virus becomes undetectable and monitor safety to see which approach is more effective.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VIRAL HEPATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigative
Valencia, 46014, Spain
-
Investigative Site
Brussels, 1020, Belgium
-
Investigative Site
Brussels, 1070, Belgium
-
Investigative Site
Edegem, 2650, Belgium
-
Investigative Site
Sofia, 1407, Bulgaria
-
Investigative Site
Sofia, 1431, Bulgaria
-
Investigative Site
Stara Zagora, 6003, Bulgaria
-
Investigative Site
Clichy, 92110, France
-
Investigative Site
Créteil, 94000, France
-
Investigative Site
Limoges, 87042, France
-
Investigative Site
Rennes, 35000, France
-
Investigative Site
Toulouse, 31059, France
-
Investigative Site
Hanover, 30625, Germany
-
Investigative Site
Chisinau, 2025, Moldova
-
Investigative Site
Amsterdam, 1081 HV, Netherlands
-
Investigative Site
Nijmegen, 6525 GA, Netherlands
-
Investigative Site
Rotterdam, 3015 GD, Netherlands
-
Investigative Site
Karachi, 74800, Pakistan
-
Investigative Site
Karachi, 75600, Pakistan
-
Investigative Site
Lahore, 54800, Pakistan
-
Investigative Site
Rawalpindi, 46000, Pakistan
-
Investigative Site
Bucharest, 021105, Romania
-
Investigative Site
Bucharest, 022328, Romania
-
Investigative Site
Bucharest, 030303, Romania
-
Investigative Site
Barcelona, 08028, Spain
-
Investigative Site
Madrid, 28064, Spain
-
Investigative Site
Kyiv, 01135, Ukraine
-
Investigative Site
London, E1 1BB, United Kingdom
-
Investigative Site
London, SE5 9RS, United Kingdom
-
Investigative Site
Manchester, M8 5RB, United Kingdom
-
Investigative Site
Nottingham, NG7 2UH, United Kingdom
Conditions
Explore the condition pages connected to this study.